Shannon Maude Research Program

Ongoing Research

Clinical Evaluation of Chimeric Antigen Receptor (CAR) T-cells to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Researchers are developing and evaluating chimeric antigen receptor (CAR)-modified T-cells to treat children with acute lymphoblastic leukemia (ALL).

Use of Targeted Cancer Therapies to Treat High-risk Subtypes of Pediatric Acute Lymphoblastic Leukemia (ALL)

Early stage clinical trials in partnership with the Children’s Oncology Group (COG) are being developed to evaluate the efficacy and safety of a combination of ruxolitinib with standard chemotherapy to treat high-risk ALL with dysregulated Jak /STAT signaling mutations.